Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · CFR · Title 21 — Food and Drugs · Part 870 — Cardiovascular Devices · § 870.3535

§ 870.3535. Intra-aortic balloon and control system.

361 words·~2 min read·/us/cfr/t21/s§ 870.3535·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

(a)Identification. An intra-aortic balloon and control system is a prescription device that consists of an inflatable balloon, which is placed in the aorta to improve cardiovascular functioning during certain life-threatening emergencies, and a control system for regulating the inflation and deflation of the balloon. The control system, which monitors and is synchronized with the electrocardiogram, provides a means for setting the inflation and deflation of the balloon with the cardiac cycle.
(b)Classification.
(1)Class II (special controls) when the device is indicated for acute coronary syndrome, cardiac and non-cardiac surgery, or complications of heart failure. The special controls for this device are:
(i)Appropriate analysis and non-clinical testing must be conducted to validate electromagnetic compatibility and electrical safety of the device;
(ii)Software verification, validation, and hazard analysis must be performed;
(iii)The device must be demonstrated to be biocompatible;
(iv)Sterility and shelf-life testing must demonstrate the sterility of patient-contacting components and the shelf life of these components;
(v)Non-clinical performance evaluation of the device must demonstrate mechanical integrity, durability, and reliability to support its intended purpose; and
(vi)Labeling must include a detailed summary of the device- and procedure-related complications pertinent to use of the device.
(2)Class III (premarket approval) when the device is indicated for septic shock and pulsatile flow generation.
(c)Date premarket approval application
(PMA)or notice of completion of product development protocol
(PDP)is required. A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before March 31, 2014, for any intra-aortic balloon and control system indicated for septic shock or pulsatile flow generation that was in commercial distribution before May 28, 1976, or that has, on or before March 31, 2014, been found to be substantially equivalent to any intra-aortic balloon and control system indicated for septic shock or pulsatile flow generation that was in commercial distribution before May 28, 1976. Any other intra-aortic balloon and control system indicated for septic shock or pulsatile flow generation shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution. [78 FR 79303, Dec. 31, 2013]
Connections1 cite this
Cited by 1 section
Citation graph
cites case law
§ 870.3535
Intra-aortic balloon and control system.
Fed. Reg.×1
Cites 0Cited by 1 across 1 source
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.